Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0PE2L
|
||||
| Former ID |
DNCL001576
|
||||
| Drug Name |
GSK2402968
|
||||
| Indication | Duchenne muscular dystrophy [ICD10:G71.0] | Phase 3 | [523702] | ||
| Company |
GlaxoSmithKline; Prosensa
|
||||
| Target and Pathway | |||||
| Target(s) | mRNA of Dystrophin | Target Info | Modulator | [523277], [532951] | |
| NetPath Pathway | IL4 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| References | |||||
| Ref 523277 | ClinicalTrials.gov (NCT01254019) A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy. U.S. National Institutes of Health. | ||||
| Ref 532951 | Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.